Safety and efficacy of abemaciclib plus endocrine therapy (ET) in elderly patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+, HER2-) advanced breast cancer: An age-specific subgroup analysis of MONARCH 2 and 3 trials Goetz, M. P., Okera, M., Wildiers, H., Campone, M., Grischke, E., Manso, L., Andre, V., Chong, A., San Antonio, B., Toi, M., Sledge, G. W. AMER ASSOC CANCER RESEARCH. 2020

View details for DOI 10.1158/1538-7445.SABCS19-P1-19-10

View details for Web of Science ID 000527012500331